-
公开(公告)号：WO2021230252A1
公开(公告)日：2021-11-18
申请号：PCT/JP2021/017940
申请日：2021-05-11
申请人： 三菱商事ライフサイエンス株式会社 , 大分県
IPC分类号： A61K39/39 , A61P37/04 , A61K36/06 , A23K10/16 , A23K20/153 , A23K50/80 , A61K31/7105
摘要： 【課題】 本発明は、魚介類に対して安価に且つ速やかに免疫を賦活させる方法を提供する。また、本発明は、従来の免疫賦活剤の連続投与によって起こる飼料効率の低下で魚介類の養殖飼料素材としては適さなかった多糖類などとは違い、連続投与が可能で且つ飼料効率を高めることが可能な魚介類の養殖飼料素材としての提供でもある。 【解決手段】 RNAを含有する酵母エキスを給与する、もしくは飼料やワクチンに配合して投与することにより、安価に且つ速やかに免疫を賦活させることを見出し本発明を完成した。
-
公开(公告)号：WO2021225657A2
公开(公告)日：2021-11-11
申请号：PCT/US2021/016966
申请日：2021-02-05
发明人： ADGUWAL, Ravindra , KUNAL, Swaraj Priyaranjan , GHOLKAR, Pratik Vinayak , NAGABHUSHANA, Kyatanahalli Srinivasa , SASTRY, Murali
IPC分类号： C09D5/32 , C12P17/10 , D06M13/352 , A61K31/407 , A61K36/06
摘要： Compositions and methods for making and using a water soluble melanin, eumelanin, pheomelanin, allomelanin and DHN-melanin pigment produced from a fungus. The water soluble melanin can be used in a radioprotective composition having at least 0.1 to at least 8.0% (wt./vol.) melanin(s), a solvent and optionally a binder(s) and/or an additive(s). The aqueous soluble melanin has uses in medical, aeronautical, industrial, cosmetic and other applications that are disclosed.
-
公开(公告)号：WO2021205451A1
公开(公告)日：2021-10-14
申请号：PCT/IL2021/050397
申请日：2021-04-07
发明人： MIZRAHI, Itzhak
摘要： A method of altering the composition of the microbiome of an adult ruminant is disclosed. The method comprises administering to the ruminant when it is the newborn stage of life, a composition which alters the amount of bacteria of the Akkermansia genus in the microbiome of the newborn ruminant, thereby altering the composition of the microbiome of the adult ruminant.
-
公开(公告)号：WO2021202988A2
公开(公告)日：2021-10-07
申请号：PCT/US2021/025564
申请日：2021-04-02
发明人： STAMETS, Paul E.
IPC分类号： A61K36/06 , A61K36/07 , A61P1/00 , A61P3/00 , A61K2236/11 , A61K2236/331 , A61K47/10 , A61K47/26 , A61K9/0053 , A61K9/48 , A61P31/14
摘要： Described herein are mushroom compositions and methods for treating, prophylaxis of, or ameliorating symptoms of one or more adverse reactions triggered by an infectious disease or condition that increases an anti-inflammatory response in a subject with such compositions. In one aspect the composition comprises an aqueous or solid fraction of a mycelium, a fermented substrate thereof, or a combination thereof optionally combined with one or more buffering agents, ethanol, and water.
-
公开(公告)号：WO2021173806A1
公开(公告)日：2021-09-02
申请号：PCT/US2021/019620
申请日：2021-02-25
申请人： ERGO HEALTH LLC
发明人： LIU, Pinghua
摘要： A method of treating diseases with the compound of Formula I is disclosed. The compound exhibits therapeutic effect to the treatment of various diseases including neurodegenerative diseases, muscular dystrophy, and cardiovascular diseases.
-
-
公开(公告)号：WO2021159213A1
公开(公告)日：2021-08-19
申请号：PCT/CA2021/050154
申请日：2021-02-12
发明人： SOLECKI, Bhavna
IPC分类号： A61K36/06 , A23L31/00 , C07D209/16 , C07F9/572
摘要： A method of manufacturing a mushroom extract, the mushroom extract made by the formulation, and pharmaceutical formulations comprising same.
-
公开(公告)号：WO2021049587A1
公开(公告)日：2021-03-18
申请号：PCT/JP2020/034361
申请日：2020-09-10
申请人： 株式会社アウレオ , 国立研究開発法人国立成育医療研究センター
IPC分类号： A61K31/716 , A23L33/10 , A61K36/06 , A61K39/395 , A61P35/00 , A61P43/00
摘要： 免疫チェックポイント阻害剤等の抗体医薬の効果を増強することができる組成物を提供する。 β－グルカンを、抗体医薬の効果を増強するための組成物の有効成分として用いる。この組成物は、免疫チェックポイント阻害を介してがんの増殖を抑制する作用効果を有する抗体医薬、例えば、ＰＤ－Ｌ１に対するモノクローナル抗体を含む抗体医薬に好適に用いられる。
-
公开(公告)号：WO2021028861A2
公开(公告)日：2021-02-18
申请号：PCT/IB2020/057615
申请日：2020-08-13
发明人： MANDE, Sharmila Shekhar , BOSE, Tungadri , BHAR, Subhrajit , DUTTA, Anirban , PINNA, Nishal Kumar
IPC分类号： G06F19/00 , G01N33/569 , C12Q1/68 , A61K31/437 , A61K36/06 , C12Q1/6883 , C12Q1/689 , C12Q2600/158 , G16B20/00 , G16B40/20 , G16H50/30
摘要： Prediabetes is an intermediary physiological condition (in between healthy and diabetic states) which may be reversed through timely intervention. A system and method for assessing the risk of prediabetes in a person has been provided. The system 100 is configured to assess individuals to check the absence or presence of prediabetic symptoms, by quantifying the abundance of sensory proteins in their microbiome. The invention relates to a defined methodology that involves assessment and categorization of the person into healthy and prediabetic based on the abundance of sensory proteins in the sample collected from the faeces of the person. The systems and methods further describe microbiota based therapeutics for treatment/ management of prediabetes through generating a therapeutic model and administering a consortium of healthy microbes which could modulate the disease microbiome composition towards a healthy equilibrium.
-
公开(公告)号：WO2021024178A2
公开(公告)日：2021-02-11
申请号：PCT/IB2020/057360
申请日：2020-08-04
IPC分类号： G06F19/00 , G01N33/569 , G12Q1/68 , A61K31/437 , A61K36/06 , G16B20/00 , G16B40/20
摘要： Multiple sclerosis (MS) is a neurodegenerative autoimmune disease affecting brain and the spinal cord which results in distorted communication between brain and rest of the body. It is necessary to assess the risk of MS at the earliest. A system and method for diagnosis and risk assessment of an individual for multiple sclerosis has been provided. The system is using a non-invasive method for risk assessment through prediction of metabolic potential of the bacteria residing in gastrointestinal tract of the individual. The system is configured to calculate a score, which is evaluated from the gut bacterial taxonomic abundance profile, indicative of its metabolic potential for production of a particular neuroactive compound. The score is subsequently used to predict the risk of the individual for MS. The present disclosure also provides microbiome based therapeutic approaches that can potentially minimize the side effects through maintaining the healthy cohort of bacteria in gut.
-
-
-
-
-
-
-
-
-
搜索结果
535 条记录 (耗时 0.025 秒)
